# Stage II-IIIa Urothelial Cancer Randomizing Pre-operative Nivolumab With or Without Relatlimab

> **NCT06237920** · PHASE2 · RECRUITING · sponsor: **The Netherlands Cancer Institute** · enrollment: 90 (estimated)

## Conditions studied

- Urologic Neoplasms
- Urogenital Neoplasms
- Neoplasms by Site
- Neoplasms
- Female Urogenital Diseases
- Female Urogenital Diseases and Pregnancy Complications
- Urogenital Diseases
- Urinary Bladder Diseases
- Male Urogenital Diseases
- Urinary Bladder Neoplasm
- Antineoplastics Toxicity

## Interventions

- **DRUG:** Nivolumab
- **DRUG:** Relatlimab

## Key facts

- **NCT ID:** NCT06237920
- **Lead sponsor:** The Netherlands Cancer Institute
- **Sponsor class:** OTHER
- **Phase:** PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** RECRUITING
- **Start date:** 2024-02-19
- **Primary completion:** 2026-07-01
- **Final completion:** 2028-08-01
- **Target enrollment:** 90 (ESTIMATED)
- **Last updated:** 2025-09-03

## Collaborators

- [object Object]

## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT06237920

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT06237920, "Stage II-IIIa Urothelial Cancer Randomizing Pre-operative Nivolumab With or Without Relatlimab". Retrieved via AI Analytics 2026-06-05 from https://api.ai-analytics.org/clinical/NCT06237920. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*